Borderline Leprosy

A form of LEPROSY in which there are clinical manifestations of both principal types (lepromatous and tuberculoid). The disease may shift toward one of these two polar or principal forms.

Also Known As:

Networked: 54 relevant articles (3 outcomes, 6 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Granuloma
2.	Lepromatous Leprosy
3.	Neuritis (Polyneuritis)
4.	Leprosy (Hansen's Disease)
5.	Tuberculoid Leprosy

Experts

1.	Nogueira, Maria Esther Salles: 2 articles (01/2015 - 04/2012)
2.	Britton, S: 2 articles (03/2004 - 11/2001)
3.	Schön, T: 2 articles (03/2004 - 11/2001)
4.	Negesse, Y: 2 articles (03/2004 - 11/2001)
5.	Sundqvist, T: 2 articles (03/2004 - 11/2001)
6.	Marcos, Elaine Valim Camarinha: 1 article (01/2015)
7.	Ura, Somei: 1 article (01/2015)
8.	de Souza-Santana, Fabiana Covolo: 1 article (01/2015)
9.	Tomimori, Jane: 1 article (01/2015)
10.	Arora, M: 1 article (10/2012)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Borderline Leprosy:

1.	Adrenal Cortex Hormones (Corticosteroids)IBA 01/01/2008 - "Intraneural extra-fascicular injection of corticosteroids improved the sensory and motor nerve function in our patient with borderline leprosy regardless of the duration of nerve function loss." 06/01/1975 - "Treatment of neuritis in borderline leprosy with rifampicin and corticosteroids--a pilot trial."
2.	Prednisone (Sone)FDA LinkGeneric 09/01/1998 - "Contribution of type 1 reactions to sensory and motor function loss in borderline leprosy patients and the efficacy of treatment with prednisone."
3.	LeprominIBA 09/01/1999 - "The lepromin test was positive in six (31.58%) patients; four were of the tuberculoid group and one each from the indeterminate and borderline leprosy groups. " 03/01/1997 - "The control group III consisted of 50 lepromin-positive, borderline leprosy patients not given any immunostimulation but given only MDT. " 03/01/1997 - "The control group II consisted of 25 lepromin-negative, borderline leprosy patients given BCG vaccination plus MDT and 25 lepromin-negative, borderline leprosy patients given killed Mycobacterium leprae (human) vaccine plus MDT. " 10/01/1981 - "[Therapy of tuberculoid and borderline leprosy by specific progressive desensitization to lepromin. " 03/01/1997 - "The test Group I, consisting of 50 lepromin-negative, borderline leprosy patients, were given low-dose Convit vaccine plus MDT. "
4.	Peroxynitrous Acid (Peroxynitrite)IBA 03/01/2004 - "Our results suggest that NO and peroxynitrite could be involved in the nerve damage following borderline leprosy." 11/01/2001 - "The aim of this study was to investigate the presence of local production of NO and peroxynitrite in borderline leprosy by using antibodies against iNOS and the product of peroxynitrite, nitrotyrosine (NT). "
5.	Rifampin (Rifampicin)FDA LinkGeneric 09/01/1994 - "In the course of a clinical trial designed to re-examine the bactericidal efficiency of 600-mg doses of rifampin (RMP) against Mycobacterium leprae, two doses of RMP, either 600 mg or 1200 mg, were administered 28 days apart to 29 previously untreated patients with lepromatous or borderline leprosy. " 06/01/1975 - "Treatment of neuritis in borderline leprosy with rifampicin and corticosteroids--a pilot trial."
6.	AntibodiesIBA 09/01/1984 - "However, the percentage of positive FLA-ABS tests caused by salivary IgA antibodies was higher in the patients with tuberculoid or borderline leprosy than in those with lepromatous leprosy. " 11/01/2001 - "The aim of this study was to investigate the presence of local production of NO and peroxynitrite in borderline leprosy by using antibodies against iNOS and the product of peroxynitrite, nitrotyrosine (NT). "
7.	3-nitrotyrosineIBA 03/01/2004 - "Nitrotyrosine localization to dermal nerves in borderline leprosy." 11/01/2001 - "Expression of inducible nitric oxide synthase and nitrotyrosine in borderline leprosy lesions." 11/01/2001 - "The aim of this study was to investigate the presence of local production of NO and peroxynitrite in borderline leprosy by using antibodies against iNOS and the product of peroxynitrite, nitrotyrosine (NT). "
8.	LipidsIBA 01/01/1964 - "STUDIES ON LIPIDS IN 'BORDERLINE' LEPROSY."
9.	anti-leprosy vaccineIBA 03/01/1997 - "The test Group I, consisting of 50 lepromin-negative, borderline leprosy patients, were given low-dose Convit vaccine plus MDT. " 03/01/1997 - "Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta." 03/01/1997 - "The present report, which describes management of lepromin-negative borderline leprosy patients with low-dose Convit vaccine, is an extension of our earlier study on the treatment of lepromatous leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy (MDT). "
10.	DapsoneFDA Link 06/01/1976 - "Serial observations on cutaneous sensation and on sweat response in hypopigmented flat patches of twenty-nine patients with tuberculoid and five with dimorphous leprosy on dapsone therapy were studied over 2 years. " 04/01/2006 - "While polar types of leprosy (TT & LL) were common in the dapsone era, more of borderline leprosy (BT & BL) cases was seen more recently. " 06/01/2003 - "A case report of fatal dapsone-induced agranulocytosis in an Indian mid-borderline leprosy patient." 06/01/2003 - "Fatal agranulocytosis in an Indian male receiving 100mg of dapsone daily, hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported. " 06/01/1991 - "A male born in 1930 was diagnosed as smear-positive borderline leprosy in 1971, and was treated with dapsone and/or sulfamethoxypyridazine from 1972 to 1980 with clinical improvement. "

Therapies and Procedures

1.	Immunotherapy 07/01/1981 - "[Result of studies of immunotherapy of lepromatous leprosy and borderline leprosy]." 10/01/2012 - "It aims to assess the additive effect of immunotherapy (Mwvaccine) with standard MDT on clinical status of untreated borderline leprosy cases and on granuloma fraction of untreated borderline leprosy cases. " 10/01/2012 - "This study reports detailed analysis of clinical parameters and clearance of granuloma in borderline leprosy patients treated with immunotherapy and chemotherapy. " 10/01/2012 - "This trial shows the potential usefulness of this approach of addition of immunotherapy to standard chemotherapy in borderline leprosy cases which leads to in faster recovery from disease reduced chances of reactions and faster granuloma clearance. " 10/01/2012 - "Clinical and histopathological evaluation of the effect of addition of immunotherapy with Mw vaccine to standard chemotherapy in borderline leprosy."
2.	Drug Therapy (Chemotherapy) 09/14/1991 - "42 (31%) of 136 Nepalese borderline leprosy patients (97 male, 39 female; age range 7-73 years) had a type-1 reaction during the first 2 years of multi-drug therapy. " 10/01/2012 - "This study reports detailed analysis of clinical parameters and clearance of granuloma in borderline leprosy patients treated with immunotherapy and chemotherapy. " 10/01/2012 - "This trial shows the potential usefulness of this approach of addition of immunotherapy to standard chemotherapy in borderline leprosy cases which leads to in faster recovery from disease reduced chances of reactions and faster granuloma clearance. " 10/01/2012 - "Clinical and histopathological evaluation of the effect of addition of immunotherapy with Mw vaccine to standard chemotherapy in borderline leprosy."
3.	Aftercare (After-Treatment) 07/01/1998 - "The individuals studied were: 5 borderline leprosy (BB) patients, 4 with a lepromatous leprosy (LL), all of whom were undergoing epidemiological surveillance after treatment and 44 household contacts: 21 of the LL and 23 contacts of the BB patients. " 05/01/1971 - "Bacilli from a number of tissues excised from cases of lepromatous and borderline leprosy, unlike mycobacteria, were found to lose their acid-fastness after treatment with pyridine."
4.	Chemoprevention 12/01/1989 - "The onset of a skin lesion of borderline leprosy in a boy 3 months after chemoprophylaxis raises the question of the nature of such a skin lesion and, indirectly, of the effectiveness of the chemoprophylaxis."
5.	Transplantation (Transplant Recipients) 03/01/1993 - "The other two cases presented with lepromatous and borderline (dimorphous) leprosy 5 months and 5 years after transplantation, respectively. "